Eli Lilly acquires AtaiBeckley and initiates Nasdaq delisting
Investing.com TR
Summary · in our words
Eli Lilly completed an acquisition of AtaiBeckley, a clinical-stage biopharmaceutical company. The transaction triggered the initiation of AtaiBeckley's delisting process from Nasdaq. The deal represents Eli Lilly's expansion into the biopharmaceutical sector through acquisition of a clinical-stage entity.
Not investment advice.
The headline and data come from Investing.com TR. The summary and analysis are Mergen's own; the full article text is not republished here.
Related news
IPO & M&A
Nvidia in talks to invest $10B in Anthropic ahead of potential $2T IPO
10 hours ago · CointelegraphDetails →
IPO & M&AAnthropic pursues up to $10 billion investment from Nvidia ahead of IPO targeting up to $100 billion valuation
12 hours ago · ParaticDetails →
IPO & M&AKKR completes 2.1 billion dollar credit facility for Integer acquisition
1 day ago · Investing.com TRDetails →
IPO & M&ABetterLife Pharma files prospectus for $100 million initial public offering
1 day ago · Investing.com TRDetails →
IPO & M&AApollo Global Management in talks to acquire Johnson & Johnson's orthopedics unit for $20 billion
1 day ago · Investing.com TRDetails →
IPO & M&ALPA receives approval to sell 145 million dollar logistics park in Peru
1 day ago · Investing.com TRDetails →